Patient-centred WISGO ‘Triangulate’ Clinical Data collection to support A & E professionals - A Feasibility Study

以患者为中心的 WISGO – Triangulate – 临床数据收集以支持 A

• 批准号: 10042896
• 金额: $ 4.78万
• 依托单位: WISGO LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10042896
• 关键词: Patient; centred; WISGO; Triangulate; Clinical

Wisgo-Medical Ltd is asking for funding to develop Triangulate, a product comprising 3 clinically mutually supportive modules which deliver a uniquely powerful innovative data bundle measuring both illness severity and likely prognostic significance. Combined, these 3 physiologically independent modules triangulate evidence of illness severity/likely prognostic significance to deliver more effective information with a greater predictive value, than is currently available from existing single assessment protocols. With the benefit of this assessment and the provision of an affordable Point-of-Care report the WISGO-Triangulate system is ideally positioned to facilitate Real Time management of clinical care, positively contributing to best clinical outcomes.The unique data bundle comprises:1\. A patient/carer, structured self-authored event report)2\. Relevant Vital Signs results supporting Clinical Early Warning Scores (NEWS/PEWS) calculation3\. A quantitative Point of Care Inflammatory Marker result.The product will progressively develop with increasingly sophisticated technology configurations. This first stage uses a tablet, hard copy reports, wearable vital signs sensors and a hard reader for the inflammatory marker result. Ultimately the product will utilise a smart phone to deliver the questionnaire, the vital signs/Clinical Early Warning scores, and a soft reader for the inflammatory marker result. This development will reflect a progressive decrease in screen size, increase in communication capability, with significant reduction of end-user costs and maintenance requirements.**Productivity-Process benefits-compared to existing procedures:**a)Converting wasted patient waiting-time into the useful activity of collecting relevant history datab)Reducing use of health care professional time when collecting vital signs datac)Improving accuracy and quality of both a) and b) aboved)Expediting the process in the A&E Department for all Inflammatory marker **result:**a)Appropriately identify those patients with nonspecific or misleading symptoms who need escalation of care(e.g. expediting progression in waiting room, prescription of antibiotic, or admission to hospital)b)Appropriately identify those patients with nonspecific or misleading symptoms who do not need escalation of care and therefore for example, antibiotics can be withheld and hospital admission avoided.

WISGO-Medical Ltd正在申请资金来开发Triangate，这是一种由3个临床上相互支持的模块组成的产品，它提供了一个独特的强大的创新数据包，可以衡量疾病的严重性和可能的预后意义。结合起来，这3个生理上独立的模块三角测量疾病严重程度/可能的预后意义的证据，以提供比现有单一评估方案目前可用的更有效的信息和更大的预测价值。WISGO-TRANGATLATION系统得益于这项评估并提供了一份负担得起的医疗点报告，非常适合促进临床护理的实时管理，对最佳临床结果做出积极贡献。独特的数据包包括：1患者/照顾者，结构化的自编事件报告)2\。相关生命体征结果支持临床预警评分(NEWS/PEWS)计算。一个量化的关注点炎症标记结果。产品将随着越来越复杂的技术配置而逐步发展。第一阶段使用平板电脑、硬拷贝报告、可穿戴式生命体征传感器和硬读取器来显示炎症标记结果。最终，该产品将使用智能手机来提供问卷、生命体征/临床早期预警评分，并使用软件阅读器来显示炎症标志物的结果。这一发展将反映出屏幕尺寸的逐步减小，通信能力的提高，终端用户成本和维护要求的显著降低。**生产力-过程优势--与现有程序相比：**a)将浪费的患者等待时间转换为收集相关历史数据的有用活动b)减少收集生命体征数据时卫生保健专业人员时间的使用)提高a)和b)两者的准确性和质量)加快急诊室对所有炎症标志物的处理**结果：**a)适当地识别那些需要升级护理的具有非特异性或误导性症状的患者(例如，加快候诊室的进展，抗生素处方或入院)b)适当地识别那些具有非特异性或误导性症状的患者，这些患者不需要升级治疗，例如，可以不使用抗生素，从而避免住院。